Corium to Present at the H.C. Wainwright 20th Annual Global Investment Conference
MENLO PARK, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple , Corium’s President and…
Corium Reports Third Quarter Fiscal 2018 Financial Results and Corporate Highlights
MENLO PARK, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third…
Corium to Report Third Quarter Fiscal 2018 Financial Results on Thursday, August 9, 2018
MENLO PARK, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ: CORI) today announced that it will report financial results for the third quarter ended June 30, 2018 on Thursday, August 9, 2018 after the close of the U.S. financial markets. Corium will host a conference…
Corium Presents Additional Positive Clinical Results at Alzheimer’s Association International Converence® 2018
Pharmacodynamic Results Further Support Therapeutic Equivalence of Corplex™ Donepezil to Aricept® MENLO PARK, Calif. , July 25, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and…
Corium Announces Issuance of Additional U.S. Patent Covering CorplexTM Donepezil Transdermal System for Alzheimer’s Disease
Second Orange Book Listable Patent Provides Expanded Coverage to 2037 MENLO PARK, Calif. , July 11, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal…
